A minituarized disposable molecular diagnostics platform for combatting coronavi...
A minituarized disposable molecular diagnostics platform for combatting coronavirus infections
The DECISION consortium is developing a new class of diagnostic platform that will transform the fight against pandemics.
The low-cost, miniaturised, disposable molecular diagnostic platform will allow for patient testing virtua...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
IRIS-COV
Market Release of a Portable Device for COVID 19 at the Poin...
3M€
Cerrado
1-SWITCH
One step switchable fluorescent probe assay for direct virus...
150K€
Cerrado
PID2020-118904RB-C22
DESARROLLO DE TESTS RAPIDOS Y ULTRASENSIBLES PARA INFECCIONE...
74K€
Cerrado
RAPID-COVID
Robust Automation and Point of Care IDentification of COVID
3M€
Cerrado
KRONO
Evaluation of a production ready portable Point of Need Pla...
2M€
Cerrado
PORTFASTFLU
Portable automated test for fast detection and surveillance...
4M€
Cerrado
Información proyecto DECISION
Duración del proyecto: 47 meses
Fecha Inicio: 2020-07-16
Fecha Fin: 2024-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The DECISION consortium is developing a new class of diagnostic platform that will transform the fight against pandemics.
The low-cost, miniaturised, disposable molecular diagnostic platform will allow for patient testing virtually anywhere, within a few minutes, with laboratory quality performance. The diagnostic platform will enable rapid detection of Covid-19 infections on-site in a multitude of settings including drive-through testing centres, physician offices, airports, hospitals and quarantine centres.
First demonstrators of the disposable molecular diagnostic platform and coronavirus test will be available five months after the start of the project and could be provided to emergency first responders and public health authorities.
The platform is powered by a next-generation nucleic acid amplification technology called Pulse Controlled Amplification (PCA®), which enables sample-to-answer workflows in 15 minutes or less.
The DECISION consortium is comprised of teams from Italy, Spain and Germany, and is highly motivated to develop a ground-breaking diagnostic solution to help the serious crisis faced across the world due to the Covid-19 epidemic.